Medicus Pharma submits optimized Phase 2 study for Teverelix to FDA
Tweet Send to a Friend
Medicus Pharma Ltd. (NASDAQ: MDCX) submitted an optimized Phase 2 clinical study protocol to the U.S. Food and Drug Administration ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
